Annogen

How do you make a stable AAV producer line, when this means producing toxic, yet essential proteins? 🧬 ☠️ To partly overcome toxicity issues during AAV production, e.g. due to the expression of Rep, vector developers are switching to inducible systems. However, gaining full control over genes such as Rep can proof challenging as: 1) promoters and enhancers are embedded in their coding regions and 2) intricate transcriptional interactions between AAV genes exist. 💡 At Annogen, we are meticulously investigated the transcriptional roles of of the full viral sequences, including p5, p19, and p40 during AAV production. Our mission: To unravel the complex transcriptional landscape during AAV production and identify the key factors influencing titer. By conducting exhaustive saturation mutagenesis screens of these regulatory elements and their variants, we aim to understand how one can: ✅ Enhance AAV yields: Boost production efficiency through optimized processes. ✅ Establish stable producer lines : Eliminating toxicity issues to enable more stable lines. ✅ Accelerate gene therapy development: Provide the foundation for more effective and cheaper treatments. We currently have a call for partners. Interested getting front row seats for this project? Reach out to info@annogen.bio today! #AAV #genetherapy #biotech #virusproduction #bioprocessing

📣Annogen community update📣 Novo Nordisk presenting SuRE results at European Association for the Study of Diabetes e.V. (EASD) this week. The results describe a novel genome-wide, quantifiable map of enhancer activity which can help better understand and treat diabetes type 2. Summarizing it’s key messages: ***Intro 1: Type 2 #diabetes (T2D) affects >400 million patients worldwide and can lead to serious complications, such as kidney, heart disease and stroke. ***Intro 2: Leveraging @Annogen’s SuRE platform, the researchers investigated how systemic energy expenditure can be enhanced to improve both 1) systemic insulin sensitivity and 2) lipid homeostasis. ***Methods: A novel, genome-wide, quantitative mapping of enhancer activity was performed using Annogen’s SuRE platform. This library, comprising >300 million unique barcoded DNA elements, was transfected into adipose progenitors, in vitro differentiated and sequenced. Additionally, gene expression data was generated by RNA-seq. ***Conclusion 1: Induction of energy expenditure in human adipocyte leads to profound changes in transcriptional regulatory circuits that may influence T2D risk. ***Conclusion 2: The work provides a novel genome-wide quantifiable mapping of enhancer activity associated with increased EE in human adipocytes to accelerate T2D genetic variant to gene mapping efforts. At Annogen, we are honored to aid in such innovations towards better treatments for patients. #genomics #novonordisk #EASD2024 #pharma

Hej allihopa! 🇸🇪 Annogen presenting novel data at ISCT, International Society for Cell & Gene Therapy in Gothenburg this week!🧬 Will you be at the #ISCTEU2024 this week? Make sure to check out Thursday's poster session to hear about Annogen's latest data on characterized, inducible promoters (#85) and expression loci (#84) for #celltherapy engineering. Two posters, presented by Joris van Arensbergen and Martijn Kelder, Ph.D. Are you not able to attend? Please contact your Annogen representative to obtain a copy of either of these posters. Annogen widely supports biopharma and academic drug developers in developing safer and more effective therapies by #geneticengineering. Our expertise lies in bespoke promoters and genomic expression loci, which we select from exhaustively screening millions of candidates in vitro and in vivo. #genetherapy #biotech #CRISPR

Not *one*, but *two* scientific posters printed and ready to go for ISCT Europe next week! 🚀 This will be my first time presenting at a conference after having started with Annogen earlier this year, which gets me excited! What on, you may wonder. Both posters are on T cell therapy, describing how gene expression can be conditionally dependent on T cell activation, which can be used to e.g. minimise exhaustion or build a reporter system: ***Poster 84 will be on specific expression loci, which give higher and better indicible expression than e.g. TRAC.*** ***Poster 85 will be on our hITA promoter, which we validated to give similar expression levels to CD69, improvements over NFAT.*** Looking forward catching up with many of you in Gothenburg. ISCT, International Society for Cell & Gene Therapy! #ISCTEU2024 #celltherapy #geneticengineering

🧬Ever wondered what goes into a groundbreaking gene therapy? There are 3 critical components for developing safe and effective cell and gene therapy treatments: ***Therapeutic gene: The targeted DNA sequence to treat a disease. ***Viral vector: The delivery vehicle for the therapeutic gene. ***Promoter: The DNA switch that controls when and where the gene turns on. Despite advancements, many gene therapies face challenges like short-lived expression and off-target effects. Here's where promoters come in. They're the key to ensuring safe, effective therapies. How would a tailored promoter elevate your gene therapy research? #genetherapy #celltherapy #promoters #biotechnology #drugdevelopment

Annogen is the unbeaten expert in unlocking tissue-specific and tailored gene expression by developing bespoke promoters and genomic expression sites. Below we explain the main reasons pharma outsources their gene expression engineering to Annogen. #celltherapy #genetherapy #drugdevelopment #viralvectors

Good morning San Diego! ☀️🐬 With the final day of #BIO2024 here, Annogen will conclude an effective get-together with leading #biopharma, all focused on using our validated in vitro and in vivo #promoters to improve the safety and efficacy of tomorrow's #advancedtherapies. We were blown away by the incredible advancements discussed! Want to learn how Annogen can help improve your gene or cell therapy pipeline? Reach out to Joris van Arensbergen or P. Victor Schut to still meet them today!

📣 Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters “Building on the safe and effective human promoters we have for our existing programs, we are excited to further establish a leadership position in the field by supporting research for additional CNS-focused cellular targets,” said Frank Thomas, president and CEO of Orchard Therapeutics - U.S.. “This work is critical as we apply our clinically-validated HSC cell therapy platform to more prevalent diseases. We look forward to utilizing Annogen’s SuRE technology to potentially advance certain pre-clinical programs.” “Annogen has gained substantial experience identifying and developing promoters for in vivo gene therapy,” Joris van Arensbergen, CEO of Annogen B.V. adds. “We are very pleased to work with a company in this field that has managed to bring autologous gene therapy through to commercialization in the U.S. and Europe. We are proud to be part of their program and to contribute to the safety and efficacy of certain pre-clinical therapies.” #genetherapy #atmp #bio2024 #biotech

Wows at #ESHG24: Annogen's talented biotinformatician Vartika Bisht presented her pioneering Ph.D. results, a joint program between Annogen and Hubrecht Institute, Developmental Biology and Stem Cell Research, at the ESHG European Society of Human Genetics in Berlin this week. We are proud of her groundbreaking results towards better understanding what causes Hypoplastic left heart syndrome. #HLHS

Our validated off-the-shelf hITA promoter specifically induces transcription upon T cell activation. This system is widely adopted for the development of therapeutic T #celltherapy products. Today Annogen’s senior scientist Daan Peric-Hupkes presents results of our hITA studies at the annual Netherlands Society of Gene and Cell Therapy NVGCT conference. Come learn more from one of our outstanding experts!